[SCHEDULE 13G] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock SEC Filing

Rhea-AI Filing Summary

Kua Khai Loon filed a Schedule 13G reporting beneficial ownership of 218,000 shares of Cyclacel Pharmaceuticals, Inc. common stock, representing 9.8% of the class. The filing shows sole voting and dispositive power over all 218,000 shares and classifies the filer as an individual (IN). The document states the securities were not acquired to change or influence control of the issuer. The filing includes issuer and filer addresses and the CUSIP 23254L876. The signature date on the filing is 08/18/2025 and the triggering event date is 07/28/2025.

Positive

• Clear disclosure of beneficial ownership amount and percentage (218,000 shares; 9.8%)
• Sole voting and dispositive power is stated, reducing ambiguity about control of the reported shares
• Certification that the shares were not acquired to influence control, consistent with Schedule 13G usage

Negative

• No additional context on how or when the shares were acquired beyond the event date
• No statement of whether the filer intends to buy or sell additional shares in the future

Insights

Securities Analyst

TL;DR: A single individual reports a 9.8% stake with sole control, a notable disclosure but presented as non-control intent.

The Schedule 13G indicates that Kua Khai Loon beneficially owns 218,000 shares (9.8%) of Cyclacel Pharmaceuticals common stock and retains sole voting and dispositive authority. Under reporting rules, a >5% stake requires disclosure; filing on Schedule 13G rather than 13D suggests the filer asserts a passive intent rather than an active attempt to influence control. All details provided are declarative: ownership amount, voting/dispositive powers, citizenship, addresses, CUSIP, and certification regarding control intent.

Corporate Governance Expert

TL;DR: Ownership above 5% is material for governance records; the filer certifies no intent to influence control.

The report supplies the necessary identification and ownership breakdown: sole voting power and sole dispositive power over the reported shares. The certification in Item 10 expressly states the securities were not acquired to change or influence control, aligning with Schedule 13G filing conditions. No group affiliations, subsidiaries, or holdings on behalf of others are reported. The disclosure is complete for a passive holder assertion based on the provided fields.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cyclacel Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

07/28/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Kua Khai Loon

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 218,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 218,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

218,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cyclacel Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Item 2.
(a)	Name of person filing: Kua Khai Loon
(b)	Address or principal business office or, if none, residence: NO 28 JALAN EKOFLORA 1/13 TAMAN EKOFLORA JOHOR BAHRU 81100 JOHOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 218,000
(b)	Percent of class: 9.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 218,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 218,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kua Khai Loon

Signature:	/s/ Kua Khai Loon
Name/Title:	Kua Khai Loon
Date:	08/18/2025

Exhibit Information

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm

FAQ

What percentage of Cyclacel Pharmaceuticals (CYCCP) does Kua Khai Loon own?

The filer reports beneficial ownership of 218,000 shares, representing 9.8% of the class.

Does the Schedule 13G indicate control intent by the filer for CYCCP?

The filing includes a certification that the securities were not acquired to change or influence control, consistent with a passive Schedule 13G filing.

What voting and dispositive powers does the filer report?

The filer reports sole voting power and sole dispositive power over all 218,000 shares and no shared powers.

When was the Schedule 13G signed and what is the event date listed?

The triggering event date listed is 07/28/2025 and the filing is signed on 08/18/2025.

Is the filer part of a group or filing on behalf of another person?

The filing indicates no group affiliation and Item 6 and Item 8 are marked Not Applicable.